The use of a synthetic cannabinoid in the management of treatment-resistant nightmares in posttraumatic stress disorder (PTSD)

CNS Neuroscience and Therapeutics

Volumn 15, Issue 1, 2009, Pages 84-88

  Fraser, George A ^a  

^a Canadian Forces Health Services   (Canada)

Author keywords

Cannabinoids; Endocannabinoids; Nabilone; Nightmares; PTSD

Indexed keywords

ANTIDEPRESSANT AGENT; CANNABINOID; HYPNOTIC AGENT; NABILONE;

ADULT; ARTICLE; BEDTIME DOSAGE; CLINICAL ARTICLE; DAYTIME SOMNOLENCE; FEMALE; HUMAN; MALE; NIGHT SWEAT; NIGHTMARE; POSTTRAUMATIC STRESS DISORDER; SLEEP TIME;

ADULT; AGED; CANNABINOIDS; DREAMS; DRUG RESISTANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; STRESS DISORDERS, POST-TRAUMATIC;

EID: 60349127390     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2008.00071.x     Document Type: Article

References (28)

1. Diagnostic and statistical manual of mental disorders, DSM-IV-TR. Washington, DC : American Psychiatric Association, 2000.
2. Kessler R, Sonnega A, Bromet E, Hughes M, Nelson CB. Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 1995 52 : 1048 1060.
3. Van Ameringen M. Posttraumatic Stress Disorder in Canada. CNS Neurosci & Ther 2009 in press.
4. Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 2006 51 (Suppl. 2 57S 62S.
5. Friedman, M. Post-traumatic and acute stress disorders: The latest assessment and treatment strategies, 4th Edition. Kansas City: Compact Clinicals, 2006 58 64.
6. Ohayon M, Shapiro C. Sleep disturbances and psychiatric disorders associated with posttraumatic stress disorder in the general population. Compr Psychiatry 2000 41 : 469 478.
7. Krakow B, Schrader R, Tandberg D, Hollifield M, Koss MP, Yau CL, Cheng DT. Nightmare frequency in sexual assault survivors with PTSD. J Anxiety Disord 2002 16 : 175 190.
8. Van Liempt S, Vermetten E, Geuze E, Westenberg H. Pharmacotherapeutic treatment of nightmares and insomnia in post traumatic stress disorders: An overview of the literature. Ann NY Acad Sci 2006 1071 : 502 507.
9. Foa EB, Cashman L, Jaycox L, Perry K. The validation of a self-report measure of posttraumatic stress disorders. Psychol Assess 1997 9 : 445 451.
10. Witkin JM, Tzavara ET, Nomikos GG. A role for cannabinoid CB1 receptors in mood and anxiety disorders. Behav Pharmacol 2005 16 : 315 331.
11. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG, Hermann H, Tang J, Hofmann C, Zieglgänsberger W, et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002 418 : 530 534.
12. Kathuria S, Gaetani S, Fegley D, Valiño F, Duranti A, Tontini A, Mor M, Tarzia G, La Rana G, Calignano A, et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003 9 : 76 81.
13. Lynch ME. Preclinical science regarding cannabinoids as analgesics: An overview. Pain Res Manage 2005 10 (Suppl. A 7A 14A.
14. 1 receptor knockout mice. Life Sci 2004 75 : 2959 2970.
15. Jiang W, Zhang Y, Xiao L, Van Cleemput J, Ji SP, Bai G, Zhang X. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 2005 115 : 3104 3116.
16. Chhatwal JP, Davis M, Maguschak KA, Ressler KJ. Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacology 2005 30 : 516 524.
17. Devane WA, Dysarz FA III., Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol 1988 34 : 605 613.
18. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, Felder CC, Herkenham M, Mackie K, Martin BR, et al. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol Rev 2002 54 : 161 202.
19. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990 346 : 561 564.
20. Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006 58 : 389 462.
21. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 2006 105 : 1 25.
22. Berlach DM, Shir Y, Ware MA. Experience with the synthetic cannabinoid in chronic noncancer pain. Pain Med 2006 7 : 25 29.
23. Wissel J, Haydn T, Muller J, Brenneis C, Berger T, Poewe W, Schelosky LD. Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain. A double-blind placebo-controlled cross-over trial. J Neurol 2006 20 : 2218 2220.
24. Glass RM, Uhlenhuth EH, Hartel FW, Schuster CR, Fischman MW. Single-dose study of nabilone in anxious volunteers. J Clin Pharmacol 1981 21 : 383S 396S.
25. Fabre LF, McLendon D. The efficacy and safety of nabilone (a synthetic cannabinoid) in the treatment of anxiety. J Clin Pharmacol 1981 21 : 377S 382S.
26. Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential. J Psychopharmacol 2005 19 : 293 300.
27. Bartolucci G. Nabilone and posttraumatic stress disorder in a user of therapeutic marijuana. Four Zero One Pharma, August 2004.
28. CESAMET™ (nabilone) Product Monograph. Valeant Canada, Ltd. Montreal, Quebec, Canada, 2006.